Drosophila CRISPR/Cas9 Genome Editing
Services
Online Inquiry
The clustered regularly interspaced short palindromic repeat (CRISPR) system was found as a bacterial immune system against invading viruses and plasmids. The class II relying on a single Cas protein with multiple domains, CRISPR/Cas9 system has been confirmed over the past decade the most widely studied and efficient tool to selectively mutagenize specific regions of the genome, and allow sophisticated and detailed mechanistic studies to be performed in a variety of organisms including Drosophila.
CD BioSciences as one of the transgenic Drosophila strain designers, we use leading edge technology to facilitate your exploration in life science. Our unique platform can meet customers' personalized research needs. Our services range from oligonucleotides customization to CRISPR editing, as well as off-target effect analysis. Our professional Ph.D. teams monitor every step of the operations guaranteeing your entire projects.
In Drosophila, the CRISPR/Cas9 system has been used to interrupt, delete, and replace genes. Cas9-induced double-strand breaks (DSBs) trigger DNA repair through two cellular pathways, non-homologous end joining (NHEJ) introduces small insertions and deletions (indels), and homologous directed repair (HDR) mediates precise repair, both of which can be used in genome editing.
Compared with ZFN and TALEN, the CRISPR/Cas9 system has distinct advantages in Drosophila gene editing: (1) more potential PAM sites can be found in the genome; (2) we provide germline expression of Cas9 and sgRNA Drosophila mutant lines, which greatly improves efficiency; (3) gene editing in Drosophila using the CRISPR/Cas9 system has high success rate. The CRISPR/Cas9 system has been effectively used to achieve knockout of loss-of-function genes with mutagenesis rates as high as 75-99%.
Fig.1 CRISPR/Cas9 Genome Editing Strategic Planning Flowchart (Gratz SJ et al, 2015)
We offer a CRISPR Drosophila general service includes design, cloning, microinjection, screening, validation and population building to bring you genetically edited Drosophila. Just tell us the name of the gene and how you want to edit it. We propose the best strategies and complete the rest of the steps for you.
Drosophila in vivo CRISPR/Cas9 genome editing platform has a broad usage in fundamental research and drug management. Click here if you want to learn more.
In our Drosophila Center, the Cas9 protein of these transgenic Drosophila strains can be specifically expressed in germ cells according to your needs. Cas9 transgenic lines with different chromosomes are available, so fertile progeny can be obtained by using Cas9 transgenic lines with different chromosomes, and Cas9 can be easily removed by hybridization.
CD BioSciences is a specialist provider of gene editing solutions for in vivo and in vitro disease Drosophila model construction, target gene knock-out/knock-in/CRISPRi/CRISPRa and other research needs. With years of expertise, our scientists provide clients with high-quality and powerful Drosophila transgenic strategy to study disease and development mechanisms, gene function, drug screening, and treatment strategy, etc. If you have any questions or requirements, please feel free to contact us.
Case 1
Reference
For research use only. Not intended for any clinical use.
Related Services